Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial

Sawako Kato, Shoichi Maruyama, Hirofumi Makino, Jun Wada, Daisuke Ogawa, Takashi Uzu, Hisazumi Araki, Daisuke Koya, Keizo Kanasaki, Yutaka Oiso, Motomitsu Goto, Akira Nishiyama, Hiroyuki Kobori, Enyu Imai, Masahiko Ando, Seiichi Matsuo

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Several studies have demonstrated that spironolactone has an anti-albuminuric property in diabetic nephropathy. As an adverse event, spironolactone often induces the elevation of creatinine levels with hypotension and hyperkalemia. Therefore, we aimed to evaluate the efficacy and safety of spironolactone in Japanese patients with type 2 diabetes treated with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Methods: Fifty-two Japanese patients with diabetic nephropathy and albuminuria (100 mg/gCr–2000 mg/gCr) treated with renin–angiotensin system (RAS) blockade were enrolled in a prospective, randomized, open-label study. The patients were subjected to add-on treatment with spironolactone 25 mg once daily and compared with matched controls for 8 weeks. The primary outcome was a reduction in the rate of albuminuria at 8 weeks compared with the baseline value. This study was registered with UMIN Clinical Trials Registry (000008016). Results: Albuminuria was reduced by 33 % (95 % confidence interval: 22–54; P = 0.0002) at 8 weeks with spironolactone. In the spironolactone group, blood pressure tended to lower and the estimated glomerular filtration rate (eGFR) was significantly decreased compared to those in the control group. When adjusted by systolic blood pressure and eGFR, spironolactone treatment still showed a significant effect on albuminuria reduction in a linear mixed model (coefficient ± standard error; 514.4 ± 137.6 mg/gCr, P 

Original languageEnglish
Pages (from-to)1098-1106
Number of pages9
JournalClinical and Experimental Nephrology
Volume19
Issue number6
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Spironolactone
Diabetic Nephropathies
Randomized Controlled Trials
Albuminuria
Blood Pressure
Glomerular Filtration Rate
Hyperkalemia
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Hypotension
Type 2 Diabetes Mellitus
Registries
Linear Models
Creatinine
Clinical Trials
Confidence Intervals
Safety
Control Groups
Therapeutics

Keywords

  • Albuminuria
  • Diabetic nephropathy
  • Randomized study
  • Spironolactone

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Physiology (medical)

Cite this

Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy : a multicenter, randomized clinical trial. / Kato, Sawako; Maruyama, Shoichi; Makino, Hirofumi; Wada, Jun; Ogawa, Daisuke; Uzu, Takashi; Araki, Hisazumi; Koya, Daisuke; Kanasaki, Keizo; Oiso, Yutaka; Goto, Motomitsu; Nishiyama, Akira; Kobori, Hiroyuki; Imai, Enyu; Ando, Masahiko; Matsuo, Seiichi.

In: Clinical and Experimental Nephrology, Vol. 19, No. 6, 01.12.2015, p. 1098-1106.

Research output: Contribution to journalArticle

Kato, S, Maruyama, S, Makino, H, Wada, J, Ogawa, D, Uzu, T, Araki, H, Koya, D, Kanasaki, K, Oiso, Y, Goto, M, Nishiyama, A, Kobori, H, Imai, E, Ando, M & Matsuo, S 2015, 'Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial', Clinical and Experimental Nephrology, vol. 19, no. 6, pp. 1098-1106. https://doi.org/10.1007/s10157-015-1106-2
Kato, Sawako ; Maruyama, Shoichi ; Makino, Hirofumi ; Wada, Jun ; Ogawa, Daisuke ; Uzu, Takashi ; Araki, Hisazumi ; Koya, Daisuke ; Kanasaki, Keizo ; Oiso, Yutaka ; Goto, Motomitsu ; Nishiyama, Akira ; Kobori, Hiroyuki ; Imai, Enyu ; Ando, Masahiko ; Matsuo, Seiichi. / Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy : a multicenter, randomized clinical trial. In: Clinical and Experimental Nephrology. 2015 ; Vol. 19, No. 6. pp. 1098-1106.
@article{74af057f0a2043918521212cbeb7f839,
title = "Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial",
abstract = "Background: Several studies have demonstrated that spironolactone has an anti-albuminuric property in diabetic nephropathy. As an adverse event, spironolactone often induces the elevation of creatinine levels with hypotension and hyperkalemia. Therefore, we aimed to evaluate the efficacy and safety of spironolactone in Japanese patients with type 2 diabetes treated with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Methods: Fifty-two Japanese patients with diabetic nephropathy and albuminuria (100 mg/gCr–2000 mg/gCr) treated with renin–angiotensin system (RAS) blockade were enrolled in a prospective, randomized, open-label study. The patients were subjected to add-on treatment with spironolactone 25 mg once daily and compared with matched controls for 8 weeks. The primary outcome was a reduction in the rate of albuminuria at 8 weeks compared with the baseline value. This study was registered with UMIN Clinical Trials Registry (000008016). Results: Albuminuria was reduced by 33 {\%} (95 {\%} confidence interval: 22–54; P = 0.0002) at 8 weeks with spironolactone. In the spironolactone group, blood pressure tended to lower and the estimated glomerular filtration rate (eGFR) was significantly decreased compared to those in the control group. When adjusted by systolic blood pressure and eGFR, spironolactone treatment still showed a significant effect on albuminuria reduction in a linear mixed model (coefficient ± standard error; 514.4 ± 137.6 mg/gCr, P ",
keywords = "Albuminuria, Diabetic nephropathy, Randomized study, Spironolactone",
author = "Sawako Kato and Shoichi Maruyama and Hirofumi Makino and Jun Wada and Daisuke Ogawa and Takashi Uzu and Hisazumi Araki and Daisuke Koya and Keizo Kanasaki and Yutaka Oiso and Motomitsu Goto and Akira Nishiyama and Hiroyuki Kobori and Enyu Imai and Masahiko Ando and Seiichi Matsuo",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s10157-015-1106-2",
language = "English",
volume = "19",
pages = "1098--1106",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy

T2 - a multicenter, randomized clinical trial

AU - Kato, Sawako

AU - Maruyama, Shoichi

AU - Makino, Hirofumi

AU - Wada, Jun

AU - Ogawa, Daisuke

AU - Uzu, Takashi

AU - Araki, Hisazumi

AU - Koya, Daisuke

AU - Kanasaki, Keizo

AU - Oiso, Yutaka

AU - Goto, Motomitsu

AU - Nishiyama, Akira

AU - Kobori, Hiroyuki

AU - Imai, Enyu

AU - Ando, Masahiko

AU - Matsuo, Seiichi

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: Several studies have demonstrated that spironolactone has an anti-albuminuric property in diabetic nephropathy. As an adverse event, spironolactone often induces the elevation of creatinine levels with hypotension and hyperkalemia. Therefore, we aimed to evaluate the efficacy and safety of spironolactone in Japanese patients with type 2 diabetes treated with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Methods: Fifty-two Japanese patients with diabetic nephropathy and albuminuria (100 mg/gCr–2000 mg/gCr) treated with renin–angiotensin system (RAS) blockade were enrolled in a prospective, randomized, open-label study. The patients were subjected to add-on treatment with spironolactone 25 mg once daily and compared with matched controls for 8 weeks. The primary outcome was a reduction in the rate of albuminuria at 8 weeks compared with the baseline value. This study was registered with UMIN Clinical Trials Registry (000008016). Results: Albuminuria was reduced by 33 % (95 % confidence interval: 22–54; P = 0.0002) at 8 weeks with spironolactone. In the spironolactone group, blood pressure tended to lower and the estimated glomerular filtration rate (eGFR) was significantly decreased compared to those in the control group. When adjusted by systolic blood pressure and eGFR, spironolactone treatment still showed a significant effect on albuminuria reduction in a linear mixed model (coefficient ± standard error; 514.4 ± 137.6 mg/gCr, P 

AB - Background: Several studies have demonstrated that spironolactone has an anti-albuminuric property in diabetic nephropathy. As an adverse event, spironolactone often induces the elevation of creatinine levels with hypotension and hyperkalemia. Therefore, we aimed to evaluate the efficacy and safety of spironolactone in Japanese patients with type 2 diabetes treated with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Methods: Fifty-two Japanese patients with diabetic nephropathy and albuminuria (100 mg/gCr–2000 mg/gCr) treated with renin–angiotensin system (RAS) blockade were enrolled in a prospective, randomized, open-label study. The patients were subjected to add-on treatment with spironolactone 25 mg once daily and compared with matched controls for 8 weeks. The primary outcome was a reduction in the rate of albuminuria at 8 weeks compared with the baseline value. This study was registered with UMIN Clinical Trials Registry (000008016). Results: Albuminuria was reduced by 33 % (95 % confidence interval: 22–54; P = 0.0002) at 8 weeks with spironolactone. In the spironolactone group, blood pressure tended to lower and the estimated glomerular filtration rate (eGFR) was significantly decreased compared to those in the control group. When adjusted by systolic blood pressure and eGFR, spironolactone treatment still showed a significant effect on albuminuria reduction in a linear mixed model (coefficient ± standard error; 514.4 ± 137.6 mg/gCr, P 

KW - Albuminuria

KW - Diabetic nephropathy

KW - Randomized study

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=84951906215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951906215&partnerID=8YFLogxK

U2 - 10.1007/s10157-015-1106-2

DO - 10.1007/s10157-015-1106-2

M3 - Article

C2 - 25795029

AN - SCOPUS:84951906215

VL - 19

SP - 1098

EP - 1106

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 6

ER -